Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Recruiting a transcription factor in the liver to prevent atherosclerosis
Alan D. Attie
Alan D. Attie
View: Text | PDF
Commentary

Recruiting a transcription factor in the liver to prevent atherosclerosis

  • Text
  • PDF
Abstract

Hypertriglyceridemia is associated with obesity, diabetes, and atherosclerosis. While lipoprotein lipase (LPL) hydrolyzes triglyceride (TG) cargo into remnant lipoproteins with atherogenic properties, how remnant lipoprotein clearance relates to atherosclerosis in people with diabetes remains unclear. In this issue of the JCI, Shimizu-Albergine et al. examined the effects of the basic leucine zipper transcription factor CREBH, which induces genes that activate LPL in mouse models of type I diabetes. Overexpression of a CREBH fragment reduced apolipoprotein C3 (APOC3) levels, which reduced plasma TGs. Notably, the TGs were lowered by a mechanism that was independent of LPL, and atherosclerosis was alleviated by enhanced lipoprotein remnant clearance as opposed to increased lipolysis of TG-rich lipoprotein precursors. A proinflammatory mechanism likely underlies the atherogenicity of remnant lipoproteins. These findings suggest that modifying CREBH expression in the liver may ameliorate atherosclerosis and, perhaps, other diabetes complications.

Authors

Alan D. Attie

×

Figure 1

Enhanced lipoprotein remnant clearance ameliorates atherosclerosis in mice ectopically expressing CREBH.

Options: View larger image (or click on image) Download as PowerPoint
Enhanced lipoprotein remnant clearance ameliorates atherosclerosis in mi...
(A) In diabetes-related atherosclerosis, triglyceride-rich lipoproteins, VLDL, and chylomicrons (not shown) form remnant lipoproteins after lipoprotein lipase–mediated (LPL-mediated) triglyceride hydrolysis. Lipids associated with the lipoprotein particles are subject to oxidation. Oxidized lipids form complexes with proteins and bind to pattern recognition receptors on macrophages, inducing proinflammatory stimuli. Glucose can also form advanced glycosylation end products (AGEs), which bind to a distinct receptor for AGEs, termed RAGE. (B) Liver-specific expression of CREBH increases APOE, a ligand that mediates clearance of remnant particles and decreases APOC3, which can interfere with remnant clearance. CREBH also enhances the cell surface expression of the Lrp1 protein, one of several receptors that mediate remnant clearance. Clearance of remnant particles from the circulation reduces diabetes-related atherosclerosis. FFAs, free fatty acids.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts